✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Merestinib is an investigational drug.
There have been 8 clinical trials for Merestinib. The most recent clinical trial was a Phase 1 trial, which was initiated on May 19th 2016.
The most common disease conditions in clinical trials are Neoplasm Metastasis, Neoplasms, and Lymphoma, Non-Hodgkin. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Jacqueline Garcia, MD.
There are eighteen US patents protecting this investigational drug and two hundred and ninety international patents.
Recent Clinical Trials for Merestinib
|Merestinib on Bone Metastases in Subjects With Breast Cancer||Eli Lilly and Company||Phase 1|
|Merestinib on Bone Metastases in Subjects With Breast Cancer||University of Utah||Phase 1|
|Combination Merestinib and LY2874455 for Patients With Relapsed or Refractory Acute Myeloid Leukemia||Eli Lilly and Company||Phase 1|
Top disease conditions for Merestinib
Top clinical trial sponsors for Merestinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Merestinib||See Plans and Pricing||Controlled release dosage form||TRIASTEK, INC. (Nanjing, CN)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Methods of treating a neuroendocrine tumor||SCRIPPS HEALTH (San Diego, CA)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Oral drug dosage forms having desired drug release profiles and uses thereof||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Tank-binding kinase inhibitor compounds||Gilead Sciences, Inc. (Foster City, CA)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Compartmented pharmaceutical dosage forms||Triastek, Inc. (Nanjing, CN)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Targeted therapeutics||MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)||See Plans and Pricing|
|Merestinib||See Plans and Pricing||Polymorphic compounds and uses thereof||Aldeyra Therapeutics, Inc. (Lexington, MA)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Merestinib||Australia||AU2017261372||2036-05-05||See Plans and Pricing|
|Merestinib||Canada||CA3023278||2036-05-05||See Plans and Pricing|
|Merestinib||China||CN107847398||2036-05-05||See Plans and Pricing|
|Merestinib||European Patent Office||EP3452003||2036-05-05||See Plans and Pricing|
|Merestinib||European Patent Office||EP3981392||2036-05-05||See Plans and Pricing|
|Merestinib||Hong Kong||HK1249728||2036-05-05||See Plans and Pricing|
|Merestinib||Japan||JP2019520866||2036-05-05||See Plans and Pricing|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|